| abstract |
FIELD: pharmaceuticals. n SUBSTANCE: group of inventions relates to construction and use of molecules of trispecific killer-attracting agents. Proposed is a compound for treating a malignant tumour expressing a tumour antigen, containing an NK-attracting domain containing amino acid residues 1-240 SEQ ID No.1 or amino acid residues 19-140 SEQ ID No.14; an NK-activating domain containing an amino acid sequence SEQ ID No.15 or amino acid sequence SEQ ID No.15 containing an amino acid substitution N72D or an amino acid substitution N72A; a first flanking polypeptide binding the NK-attracting domain and the NK-activating domain; a guiding domain, binding specifically to said tumour antigen; and a second flanking polypeptide binding the NK-activating domain and the guiding domain. In particular, proposed is a compound containing an amino acid sequence SEQ ID No.1 or SEQ ID No. 14. n EFFECT: trispecific killer-attracting agents induce NK cell proliferation and prolonged survival thereof, can serve as an ADCC mediator, and allow NK cells to be grown without the need for extracorporeal genetic modification and gene therapy. n 24 cl, 22 dwg, 3 tbl, 4 ex |